sefullness of infliximab as a second tumor necrosis factor inhibitor in patients with rheumatoid arthritis with inadequate response to tumor necrosis factor inhibitor
Phase 4
- Conditions
- rheumatoid arthritis
- Registration Number
- JPRN-UMIN000023006
- Lead Sponsor
- Osaka City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 1
Inclusion Criteria
Not provided
Exclusion Criteria
1) The patients with inadequate response to IFX after 6-weekloading administration 2) The patients with arthritic condition other than Ra 3) The patients who is planned to undergo surgery 4) Patients with allergy to IFX 5) Patients who is pregnant or lactate 6)patients who have received IFX administration 7) Those who are not approved to be eligible to this study by corresponding researcher or co-researchers
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method